In the phase IIB LUX-Lung 7 trial, Afatinib demonstrated superior progression-free survival (PFS) compared to first-generation Gefitinib in the first-line treatment of advanced NSCLC with EGFR mutations, along with a slight trend toward improved overall survival (OS) [15,16]. Here, EGFR is linked to non-small cell lung carcinoma.